News & Events

October 8, 2020

FibroGenesis Named #2 Most Innovative Company of 2020  

Read More

October 1, 2020

FibroGenesis Announces Collaboration Agreement with Brazilian Biotech R4D  Read More

 

September 28, 2020

FibroGenesis Announces Manufacturing Agreement  Read More

 

August 12, 2020

FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting  Read More

 

July 21, 2020

FibroGenesis Reduces COVID-19 Lung Scarring in Animal Model  Read More

 

July 1, 2020

FibroGenesis Identifies Mechanism Responsible for Blocking COVID-19 Lung Inflammation  Read More

May 21, 2020

FibroGenesis Announces COVID-19 Breakthrough  Read More

April 21, 2020

FibroGenesis Files Its Landmark 200th Patent  Read More

 

April 1, 2020

FibroGenesis Files Expanded Patent Coverage for its Fibroblast Cell Therapy to treat Coronavirus (COVID-19) ARDS Read More

 

March 10, 2020

FibroGenesis Files Patent to Treat Coronavirus (COVID-19) Acute Respiratory Distress Syndrome (ARDS)  Read More

 

February 3, 2020

FibroGenesis to Present at LSX World Congress  Read More

 

January 28, 2020

SpinalCyte Changes Name To FibroGenesis  Read More

December 12, 2019

SpinalCyte CEO, Pete O'Heeron named to 30 Best CEO of 2020 List

See List Here

Read Interview Here

Read Press Release Here

 

December 11, 2019

SpinalCyte Announces New Australian Patent  Read More

 

October 23, 2019

CEO/CFO Magazine Interviews SpinalCyte CEO, Pete O'Heeron  Read More

 

October 21, 2019

SpinalCyte to Present at BIO Investor Forum  Read More

 

October 15, 2019

SpinalCyte Announces New Japanese Patent  Read More

 

September 19, 2019

SpinalCyte Announces New International Patent  Read More

June 5, 2019

SpinalCyte to Present at Boao Forum in Qingdao, China  Read More

 

May 15, 2019

SpinalCyte Launches Initiative to Highlight Advances in Fibroblast Technology  Read More

March 28, 2019

SpinalCyte to Provide Clinical Trial Update at the 2019 International Society for the Advancement of Spine Surgery Annual Meeting  Read More

 

March 18, 2019

SpinalCyte to Present at China Focus @ Europe Vienna, Austria  Read More

 

March 11, 2019

SpinalCyte Announces Two New Patents  Read More

 

February 4, 2019

SpinalCyte to Present at the 2019 BIO CEO & Investor Conference  Read More

 

January 8, 2019

SpinalCyte Announces New International Patent  Read More

November 28, 2018

SpinalCyte Press Release FDA IND Acceptance Read More

 

November 14, 2018

SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection Read More

 

November 7, 2018

SpinalCyte Announces EU and Hong Kong Patents Read More

 

October 25, 2018

SpinalCyte Announces Sustained Improvement in Pain Scores at 12-Month Endpoint  Read More

 

October 11, 2018

SpinalCyte Announces 4th Peer Reviewed Publication On CybroCell Technology  Read More

 

August 28, 2018

SpinalCyte, LLC Announces New U.S. Patent  Read More

 

July 31, 2018

SpinalCyte Announces Publication of Fibroblast Study in Journal of Translational Medicine Read More

 

May 17, 2018

SpinalCyte Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018 Read More

 

April 12, 2018

SpinalCyte Applies with FDA to Expand Human Clinical Trial of CybroCell™ Dermal Fibroblasts as Investigational New Drug (IND) Read More
 

April 3, 2018

SpinalCyte Announces Positive MRI Results For Phase 1/Phase 2 Landmark Human Trial  Read More
 

February 13, 2018

SpinalCyte Announces Landmark Human Trial and Suggests Treatment Could Eliminate Need for Opioids in Some Patients  Read More

December 27, 2017
SpinalCyte, LLC Announces 25th Patent Read More

September 20, 2017
SpinalCyte Announces New Australian Patent Read More

July 20, 2017
SpinalCyte Announces New Japanese Patent Read More

April 27, 2017
SpinalCyte, LLC Receives New Australian Patent Read More

April 6, 2017
SpinalCyte, LLC Receives New European Patent Read More

March 14, 2017
First Fibroblast Injection Performed in SpinalCyte’s Landmark Trial for Spinal Disc Regeneration Read More

February 9, 2017
SpinalCyte Receives New U.S. Patent Read More

January 25, 2017
SpinalCyte Enrolls First Patient in Phase I Clinical Trial Read More

January 6, 2017
SpinalCyte, LLC Receives New U.S. Patent Read More

December 13, 2016
SpinalCyte, LLC Receives Institutional Review Board Approval for Phase I Clinical Trial

May 4, 2016

SpinalCyte Receives New U.S. Patent for Biodegradable and Resorbable Structure

April 22, 2016
SpinalCyte, LLC Receives New Canadian Patent for Spinal Disc Tissue Engineering

April 19, 2016
SpinalCyte Announces Landmark Scientific Breakthrough From Phase II Animal Trials

April 15, 2016
SpinalCyte, LLC Announces Publication in Global Spine Journal

March 29, 2016
SpinalCyte, LLC Announces New Results from Phase II Animal Trials of Cell Therapy to Regenerate the Spinal Disc 

January 8, 2016
SpinalCyte, LLC Receives New Chinese Patent for Spinal Disc Tissue Engineering

October 25, 2015
SpinalCyte, LLC Presents at MENA Private Equity & Venture Capital Summit

October 14, 2015
SpinalCyte, LLC Receives New Australian Patent for Spinal Disc Tissue Engineering

September 22, 2015
SpinalCyte Receives New U.S. Patent for Tissue Engineering

June 16, 2014
SpinalCyte, LLC Announces Final Animal Trials for Spinal Disc Tissue Engineering

May 20, 2014
SpinalCyte Receives U.S. Patent

Fibroblast cells.jpg
FibroGenesis

 Copyright © 2020 FibroGenesis. All rights reserved.